Chemotherapy Induced Anemia - Epidemiology Forecast - 2032

DelveInsight’s "Chemotherapy Induced Anemia – Epidemiology Forecast – 2032" report delivers an in-depth understanding of the historical and forecasted epidemiology of Chemotherapy Induced Anemia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chemotherapy Induced Anemia: Disease Understanding

Chemotherapy Induced Anemia Overview

Anemia is a frequent but insidious complication of cancer and its cytotoxic chemotherapy. According to the World Health Organization (WHO) definition, anemia occurs when hemoglobin (Hb) levels drop below 12 g/dL for women and 13 g/dL for men, and severity ranges from mild to severe or life-threatening. Anemia contributes to debilitating fatigue, lethargy, cardiovascular problems, shortness of breath, and reduced cognitive function in individuals who often already have significant morbidity and diminished quality of life (QOL) due to their malignancy.

When anemia occurs as an adverse event consequent to the toxic effect of anticancer treatment, it is called Chemotherapy Induced Anemia (CIA). The etiology of CIA is multifactorial; the primary causes are underlying cancer and the effects of chemotherapy. Anemia resulting from underlying cancer—known as the anemia of inflammation—causes cytokine release in the patient, leading to decreased erythropoietin production by the kidney, as well as restricted availability of iron. This process results in the condition known as functional iron deficiency. Anemia due to chemotherapy is often caused by myelosuppression. In addition, certain chemotherapeutic agents, especially platinum, can result in renal dysfunction, which can further decrease erythropoietin production. Chemotherapy regimens that contain cisplatin, used to treat lung and ovarian cancer, can be associated with significant anemia in 30% or more of treated patients. Chemotherapy agents such as docetaxel are also strongly associated with Chemotherapy Induced Anemia. Chemotherapy agents that are less myelosuppressive and less nephrotoxic are less likely to be associated with anemia.

Although CIA is one of the most common side effects of chemotherapy, it is often not recognized and is frequently undertreated. It can adversely affect long-term patient outcomes, as the anemic environment may limit the effectiveness of some chemotherapy agents. The incidence and severity of CIA depend on various factors, including the type, schedule, and intensity of therapy administered, or whether the patient has received prior myelosuppressive chemotherapy, radiation therapy, or both. An estimated 30–90% of cancer patients receiving chemotherapy develop anemia.

Correction of anemia can be achieved by treating the underlying etiology or providing supportive care that may entail transfusion with packed red blood cells (PRBCs) or administering erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. The first ESA approved by the US Food and Drug Administration (FDA) for treating anemia in patients receiving myelosuppressive chemotherapy was epoetin alfa, recombinant human erythropoietin (rhEpo). A second-generation rhEpo, darbepoetin alfa, has also been FDA-approved for this indication.

ESA’s use has been a constant topic of debate. Despite the clinical benefit of ESAs for CIA, both randomized clinical studies and systematic reviews demonstrated a significantly higher risk of thromboembolic events in patients receiving ESAs for CIA.

Efforts should be made to identify the etiology of anemia, and treatment should be directed to the underlying cause. However, identifying a specific causative factor can occasionally be difficult, and directed therapeutic intervention may not be effective.

Chemotherapy Induced Anemia: Epidemiology

The Chemotherapy Induced Anemia epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Chemotherapy Induced Anemia epidemiology segmented as the Incidence of Chemotherapy Induced Anemia, severity-specific cases of Chemotherapy Induced Anemia, and Incidence of Chemotherapy Induced Anemia per chemo cycles. The report includes the incident scenario of Chemotherapy Induced Anemia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Chemotherapy Induced Anemia Epidemiology

The epidemiology segment also provides the Chemotherapy Induced Anemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total incident population of Chemotherapy Induced Anemia in the 7MM countries was ~1.6 million cases in 2021.

As per the estimates, the United States had the highest diagnosed incident Chemotherapy Induced Anemia population in 2021. Among the EU5 countries, Germany had the highest incident population of Chemotherapy Induced Anemia with nearly 200,000 cases, followed by France in 2021. On the other hand, the United Kingdom had the lowest incident population of ~103k cases in 2021.

Scope of the Report
Chemotherapy Induced Anemia report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
Chemotherapy Induced Anemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Chemotherapy Induced Anemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report provides insight into the historical and forecasted patient pool of Chemotherapy Induced Anemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps recognize the growth opportunities in the 7MM concerning the patient population.
The report assesses the disease risk and burden and highlights the unmet needs of Chemotherapy Induced Anemia.
The report provides the segmentation of the Chemotherapy Induced Anemia epidemiology by incident cases of Chemotherapy Induced Anemia in the 7MM.
The report provides the segmentation of the Chemotherapy Induced Anemia epidemiology by severity-specific cases of Chemotherapy Induced Anemia in the 7MM.
The report provides the segmentation of the Chemotherapy Induced Anemia epidemiology by Incidence of Chemotherapy Induced Anemia per chemo cycles in the 7MM.

Report Highlights
11-year Forecast of Chemotherapy Induced Anemia epidemiology
7MM Coverage
Incident cases of Chemotherapy Induced Anemia
Severity-specific cases of Chemotherapy Induced Anemia
Incidence of Chemotherapy Induced Anemia per chemo cycles

KOL Views

We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What are the major factors that will drive the change in the patient population in Chemotherapy Induced Anemia during the forecast period (2019–2032)?
What are the key findings pertaining to the Chemotherapy Induced Anemia epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
What would be the total number of patients with Chemotherapy Induced Anemia across the 7MM during the forecast period (2019–2032)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
At what CAGR is the patient population expected to grow in the 7MM forecast period (2019–2032)?
What are the disease risk, burdens, and unmet needs of Chemotherapy Induced Anemia?
What are the currently available treatments for Chemotherapy Induced Anemia?

Reasons to buy

Chemotherapy Induced Anemia Epidemiology report will allow the user to:
Develop business strategies by understanding the trends shaping and driving the global Chemotherapy Induced Anemia market
Quantify patient populations in the global Chemotherapy Induced Anemia market to improve product design, pricing, and launch plans
Understand the magnitude of the Chemotherapy Induced Anemia population by its incident cases.
Understand the magnitude of the Chemotherapy Induced Anemia population by its severity-specific cases.
Understand the magnitude of the Chemotherapy Induced Anemia population by its Incidence of Chemotherapy Induced Anemia per chemo cycles
The Chemotherapy Induced Anemia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
The Chemotherapy Induced Anemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019–2032